GENE ONLINE|News &
Opinion
Blog

Gene Editing
Moderna, Life Edit To Develop In Vivo Gene Editing Therapies
2023-02-23
Treating Common Heart Disease with CRISPR-Cas9 Gene Editing
2022-12-27
Verve and Vertex Agree to Co-Develop In Vivo Gene Editing Program for Liver Disease
2022-07-21
Verve Cleared to Test Gene Editing Drug for Heart Disease in Humans
2022-05-12
TALED Tool Launches a New Era of Mitochondrial Genome Editing
2022-05-03
CRISPR Biotech Editas Obtains FDA Rare Pediatric Disease Label
2022-04-27
FDA Announces Draft Guidances on Genome Editing and CAR T Cell Therapy
2022-03-25
China Pushes for Faster Approval for Gene-Edited Crops
2022-02-15
What If Our Body’s Power Station Goes Wrong? Gene Therapy May Help
2022-02-15
GeneOnline’s Pick: Novel Biotechnologies that Made a Splash in 2021
2022-01-27
GeneOnline’s Top 10 Editor’s Picks for 2021
2021-12-23
Harnessing the potential of CRISPR-Cas9 for Gut Microbiome Gene Editing
2021-11-29
Study Advocates Cautious Application of CRISPR in Designing Therapeutics
2021-11-22
Chroma Medicine Debuts with High Hopes for “Game-Changing” Epigenetic Genome Editors
2021-11-17
Moderna Enters Gene Editing Market with Metagenomi Collaboration
2021-11-03
1 2 3 6
LATEST
Merck’s KEYNOTE-522 Success; BMS Licenses PRX019, Prothena Gets $80M
2024-06-19
Pie Medical Imaging announces enrollment completion of the FASTIII clinical trial
2024-06-18
Company Presentations at BIO 2024 Inspire Partnering
2024-06-14
GV Regains Compliance with Nasdaq Minimum Bid Price Requirement
2024-06-13
ARPA-H Fast-Tracks Biotech Startups: Funding Insights from BIO 2024 Panel
2024-06-12
Gene Therapy Innovations and Financial Challenges for the Future of Medicine
2024-06-12
BIO Releases DEI Survey in Partnership with Korn Ferry
2024-06-11
EVENT
Scroll to Top